Company Overview of Symphogen A/S
Symphogen A/S, a biopharmaceutical company, develops recombinant antibody mixture therapeutics to improve the treatment of cancer. It develops Sym004, an investigational antibody mixture targeting the epidermal growth factor receptor for patients with metastatic colorectal cancer and non-small cell lung cancer; Sym009, an antibody program against undisclosed infectious diseases; Sym013, a pre-clinical oncology pipeline product; and Sym015, a multi targeting mAb mixture program against the receptor tyrosine kinase c-MET. Symphogen A/S has a strategic collaboration with Genentech, Inc.; and Baxalta Incorporated. The company was founded in 2000 and is headquartered in Ballerup, Denmark.
Founded in 2000
Key Executives for Symphogen A/S
Chief Executive Officer and Director
Chief Scientific Officer, Medical Officer, Head of Global R&D and Co-Chairman Scientific Advisory Board
Chief Manufacturing Officer
Compensation as of Fiscal Year 2016.
Symphogen A/S Key Developments
Symphogen A/S Appoints Jesper Bramming as Chief Financial Officer
Sep 14 16
Symphogen A/S announced that Jesper Bramming has joined Symphogen as its new chief financial officer, filling the position vacated by Martin Olin, who was promoted to chief executive officer and member of the board of directors. Jesper Bramming comes to Symphogen from the CMC Biologics Group where he was chief financial officer and a member of the group management team. His responsibilities included financial accounting and reporting, legal and IT. Prior to CMC Biologics, Bramming was executive vice president and chief financial officer with Nets Holding A/S. Prior to that, for sixteen years, he held financial management level positions within the A.P: Møller-Maersk Group and was chief financial officer of Svitzer A/S. Prior to these assignments, Bramming held a number of senior positions in banking and investment management in leading European firms. He holds board seats as chairman of both Menu A/S Scandinavia Living A/S and Rejsekort A/S, and is a director of Danske Invest Management.
Symphogen A/S Announces Executive Changes Effective September 1, 2016
Aug 18 16
Symphogen A/S announced that Kirsten Drejer, M.Sc., Ph. D., Co-founder, Chief Executive Officer and Director will transition from an executive operational role to an independent member of the Board of Directors. In parallel, Martin Olin, M.Sc., E*MBA, now Chief Financial Officer, has been promoted effective 1st September to Chief Executive Officer and member of the Board of Directors. Kirsten Drejer is proposed to be elected to the Board of Directors as an independent member and will, through a transition period, be a working Board member assisting Martin Olin. Kirsten Drejer uniquely assembled a team that initially prosecuted a suite of novel antibody mixture technologies and later brought several promising drug candidates into the clinic. She has put in place a successful strategy for going forward alone and, where appropriate, with corporate partners.
Symphogen Announces Appointment of Two New Non-Executive Directors
May 11 16
Symphogen announced the appointment to the company’s Board of Directors two new Non-Executive Directors: Mr. Jeffrey H. Buchalter and Mr. Christoffer Søderberg, effective 10 May 2016. Jeffrey H. Buchalter has over thirty years’ experience in the bio/pharmaceutical industry. His experience combines strong corporate leadership allied to an extensive background in medical/clinical research with multinational organizations. He brings extensive commercial and drug development experience in oncology and other therapeutic areas. Jeffrey has been recognized for his work, receiving the Joseph F. Buckley Memorial Award from the American Cancer Society for commitment to cancer control and involvement in the oncology pharmaceutical field. He has also been a Collaborating Partner in the President’s National Dialogue on Cancer and acted as Chairman of the Board of Directors to the National Childhood Cancer Foundation in the United States. Christoffer Søderberg, has been a Director, Large Investments at Novo A/S since February 2016 leading investment processes and taking part in managing and developing the portfolio of investments. Prior to joining Novo A/S, Christoffer was a Senior Principal at the Boston Consulting Group (BCG) leading the Copenhagen Private Equity and Principal Investors practice area. Prior to joining BCG, Christoffer worked at Falck A/S as Global Head of Group Strategy and M&A, and most recently as CFO Falck Assistance. Prior to joining Falck, Christoffer worked as a Director at Carnegie Investment Banking focusing on buy-and sell-side M&A.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|